Galectin Therapeutics Inc. (GALT)
NASDAQ: GALT · Real-Time Price · USD
3.350
+0.250 (8.06%)
At close: Mar 9, 2026, 4:00 PM EDT
3.390
+0.040 (1.19%)
After-hours: Mar 9, 2026, 7:52 PM EDT
Galectin Therapeutics Employees
Galectin Therapeutics had 15 employees as of December 31, 2024. The number of employees increased by 1 or 7.14% compared to the previous year.
Employees
15
Change (1Y)
1
Growth (1Y)
7.14%
Revenue / Employee
n/a
Profits / Employee
-$2,496,133
Market Cap
215.98M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Editas Medicine | 246 |
| Protalix BioTherapeutics | 213 |
| ProQR Therapeutics | 166 |
| Molecular Partners AG | 153 |
| Arcturus Therapeutics Holdings | 111 |
| Tenaya Therapeutics | 97 |
| Compugen | 74 |
| Acumen Pharmaceuticals | 61 |
GALT News
- 2 months ago - GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with the Schall Law Firm - GlobeNewsWire
- 2 months ago - GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with The Schall Law Firm - Business Wire
- 3 months ago - Clinical Progress Drives Galectin Shares Up Post-NAVIGATE Data - Seeking Alpha
- 3 months ago - Galectin Therapeutics: NAVIGATE Data Validates The Fibrosis Thesis - Seeking Alpha
- 4 months ago - Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update - GlobeNewsWire
- 6 months ago - Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 10 months ago - Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress - GlobeNewsWire
- 1 year ago - Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update - GlobeNewsWire